Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo

Molecular and Cellular Biochemistry

Volumn 375, Issue 1-2, 2013, Pages 207-217

  Webb, Siobhan L ^a   Sanders, Andrew J ^a   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Matriptase 2; Prostate cancer; TTSP; uPA

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; MATRIPTASE; MATRIPTASE 2; UNCLASSIFIED DRUG; UROKINASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL ASSAY; CELL MOTILITY; GENE OVEREXPRESSION; GROWTH; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERINE ENDOPEPTIDASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

MAMMALIA; MUS;

EID: 84873059706     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1544-z     Document Type: Article

References (33)

1. Lang JC, Schuller DE (2001) Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer 84(2):237-243. doi: 10.1054/bjoc.2000.1586S0007092000915866
2. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB, Bae DS (2005) Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 36(6):626-633. doi: 10.1016/j.humpath.2005.03.003
3. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61(15):5692-5696
4. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM (2003) Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22(2-3):237-258
5. Wallrapp C, Hahnel S, Muller-Pillasch F, Burghardt B, Iwamura T, Ruthenburger M, Lerch MM, Adler G, Gress TM (2000) A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 60(10):2602-2606
6. Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C (2002) Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 277(40):37637-37646. doi: 10.1074/jbc.M203007200
7. Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H, Quigley JP (2003) Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 373(Pt 3):689-702. doi: 10.1042/BJ20030390
8. Szabo R, Bugge TH (2008) Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 40(6-7):1297-1316. doi: 10.1016/j.biocel.2007.11.013
9. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB (1993) Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 53(6):1409-1415
10. Tsai WC, Chu CH, Yu CP, Sheu LF, Chen A, Chiang H, Jin JS (2008) Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 24(2):89-99
11. Uhland K (2006) Matriptase and its putative role in cancer. Cell Mol Life Sci 63(24):2968-2978. doi: 10.1007/s00018-006-6298-x
12. Parr C, Sanders AJ, Davies G, Martin T, Lane J, Mason MD, Mansel RE, Jiang WG (2007) Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res 13(12):3568-3576. doi: 10.1158/1078-0432.CCR-06-2357
13. Sanders AJ, Parr C, Martin TA, Lane J, Mason MD, Jiang WG (2008) Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol 216(3):780-789. doi: 10.1002/jcp.21460
14. Odet F, Verot A, Le Magueresse-Battistoni B (2006) The mouse testis is the source of various serine proteases and serine proteinase inhibitors (SERPINs): serine proteases and SERPINs identified in Leydig cells are under gonadotropin regulation. Endocrinology 147(9):4374-4383. doi: 10.1210/en.2006-0484
15. Overall CM, Tam EM, Kappelhoff R, Connor A, Ewart T, Morrison CJ, Puente X, Lopez-Otin C, Seth A (2004) Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 385(6):493-504. doi: 10.1515/BC.2004.058
16. Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, Khovananth K, Mudd S, Mann N, Moresco EM, Beutler E, Beutler B (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320(5879):1088-1092. doi: 10.1126/science.1157121
17. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8(6):502-511. doi: 10.1016/j.cmet.2008.09.012
18. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC (1995) Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 55(21):5043-5048
19. Parr C, Jiang WG (2006) Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 119(5):1176-1183. doi: 10.1002/ijc.21881
20. Webb SL, Sanders AJ, Mason MD, Jiang WG (2012) The influence of matriptase-2 on prostate cancer in vitro: a possible role for beta-catenin. Oncol Rep 28(4):1491-1497. doi: 10.3892/or.2012.1945
21. Parr C, Watkins G, Mansel RE, Jiang WG (2004) The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10(1 Pt 1):202-211
22. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF, Puntis MC (1995) Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71(4):744-752
23. Martin TA, Parr C, Davies G, Watkins G, Lane J, Matsumoto K, Nakamura T, Mansel RE, Jiang WG (2003) Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24(8):1317-1323. doi: 10.1093/carcin/bgg072bgg072
24. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249-257. doi: 10.1038/35025220
25. Pepper MS (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21(7):1104-1117
26. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161-174. doi: 10.1038/nrc745
27. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM (2002) Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100(4):1160-1167
28. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J (1999) Proteolytic control of growth factor availability. APMIS 107(1):80-85
29. Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, Gotley DC, Quigley JP, Antalis TM (2003) Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 89(3):561-572. doi: 10.1267/THRO03030561
30. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275(34):26333-26342. doi: 10.1074/jbc.M002941200
31. Bajou K, Devy L, Masson V, Albert V, Frankenne F, Noel A, Foidart JM (2001) Role of plasminogen activator inhibitor type 1 in tumor angiogenesis. Therapie 56(5):465-472
32. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 25(4):377-388. doi: 10.1007/s10585-007-9116-4
33. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM (2004) Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 57(6):577-584